• Rhenovia Pharma

  Participated · Equity · Feb 2014

  Rhenovia Pharma, founded in 2007 and based in Mulhouse, France and Cambridge, Massachusetts, develops computer simulators that predict the effects of molecules on healthy individuals and patients with conditions such as Alzheimer's, Parkinson's, epilepsy and depression. Its biosimulation technology reduces the need for animal testing and can measure effects of neurotoxic agents including pesticides, nanoparticles, industrial emissions and chemical weapons. The platform can also aid development of antidotes to poison gas, making it relevant to civil and military protection stakeholders. Rhenovia serves three key markets—pharmaceutical, agrifood and neurotoxicity—and plans to step up development across these areas. The company has around twenty staff across France, Switzerland, Germany and the US. It recently raised €540k and intends to use additional funds to expand staff, particularly in marketing and therapeutic applications. Rhenovia plans to raise a further €2m in 2014 and is opening the new round to new investors, particularly family offices.

• Domain Therapeutics

  Participated · Equity · Jul 2012

  Domain Therapeutics focuses on discovery and development of novel therapeutics targeting GPCR-mediated immunosuppression in cancer. Its lead clinical program is an EP4R antagonist, DT-9081, and the company is advancing two additional GPCR programs including an anti-CCR8 antibody toward IND filing. Domain leverages proprietary platforms to identify first-in-class GPCR assets and is also working on biomarkers and tissue/protein expression strategies to select responsive patients. The company operates across France and Canada and has previously delivered a GPCR drug candidate in collaboration with Merck KGaA. Proceeds from the announced financing will fund clinical development of DT-9081, IND-enabling work for the two additional programs, and progression of its discovery-stage pipeline. Domain Therapeutics is a Strasbourg, France-based biopharmaceutical company specialized in discovery and development of new drug candidates targeting G protein-coupled receptors (GPCRs) in neurology, oncology and rare diseases. Led by CEO Pascal Neuville, the company identifies and develops allosteric modulators and biased ligands. It leverages an innovative business model with three revenue-generating pillars: collaborations with pharma for discovery, out-licensing of its bioSens-All™ technology, and creation of asset-centric vehicles to develop its internal preclinical pipeline. Domain recently closed a €6m non-dilutive debt financing to expand its proprietary drug portfolio and prepare the next round of financing. The financing was provided by the French Public Investment Bank, Banque Populaire Alsace Lorraine Champagne, Credit Industriel et Commercial (CIC) and Caisse d’Epargne Grand Est Europe. The company intends to use the funds to advance its programs and strengthen its position ahead of future fundraising. Domain Therapeutics focuses on discovery and early development of drug candidates that target membrane receptors, using allosteric modulators and biased ligands. Its core technologies include the bioSens-All™ platform and other proprietary approaches to identify and develop candidates. The company operates three revenue-generating pillars: collaborations with pharma for discovery, out-licensing of bioSens-All™, and creating asset-centric vehicles to develop internal preclinical candidates. In 2018 it executed these pillars via a multitarget collaboration with Boehringer Ingelheim, a license of bioSens-All™ to BMS, and the acquisition by Lundbeck of Prexton Therapeutics. Founded in 2008 and led by CEO Pascal Neuville, Domain Therapeutics is based in Strasbourg, France. The company recently secured €3.5M in funding from existing shareholder Seventure Partners to accelerate its next growth phase. Domain Therapeutics, led by CEO Pascal Neuville, is a biopharmaceutical company based in Strasbourg, France and Montreal, Canada focused on discovery and early development of small molecules targeting G protein‑coupled receptors (GPCRs). The company’s current program centers on metabotropic glutamate receptor type III (mGluR3) positive allosteric modulators (PAMs), which Domain found to demonstrate in vitro neuroprotective effects mediated by production of growth factors. Stimulating these growth factors is essential for neuron survival, underpinning the program’s rationale for Parkinson’s disease. Throughout the rest of the year Domain plans to identify the most favorable mGluR3 PAM leads to advance into proof‑of‑concept studies in Parkinson’s disease models. Financial support for the program has come from The Michael J. Fox Foundation (MJFF), which previously funded initial stages in 2012. The company received a second MJFF grant to support continued lead selection and preclinical proof‑of‑concept work. Domain Therapeutics is a Strasbourg, France-based biopharmaceutical company dedicated to the discovery and early development of small molecules targeting G-Protein Coupled Receptors (GPCRs). Led by CEO Pascal Neuville, the company discovers allosteric modulators using its proprietary DTect-All (TM) technology. Its pipeline comprises new chemical entities, ranging from hits to optimized leads for indications including schizophrenia, Parkinson’s disease and diabetes. The company plans to add some 30 high-throughput screening assays to its existing portfolio. Historically engaged in contract research for the pharmaceutical industry, Domain Therapeutics intends to use the new funds to transition toward collaborations and strategic alliances with existing clients and new partners to discover GPCR-targeting drugs. The company completed a €2m financing committed by a mix of new and existing investors.

No current team members are available.